NorthWest Biotherapeutics Inc (NWBO)

[The Danish Dude]

Ah yes, they recap the nonsense of Bent and Preusser.

First your own comment Lykiri regarding these ....

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171641646

And then Al Musella debunking

I completely disagree with the paper. Luckily it was just submitted and not peer reviewed. It would never pass peer review. The easiest fact to show they are wrong is they emphasis "post-hoc" a few times. Had they read the paper, they would have seen ,,,

— Al Musella (@AlMusella) December 23, 2022

I agree completely. Did you know the novocure trials got picked apart even worse than the dcvax trials? I am a big proponent of Optune and fought against the negativity when the vast majority of clinicians were against it. There are still a few against, even after 250+ papers

— Al Musella (@AlMusella) December 23, 2022

"This is the first SAP that has been submitted for the Trial, and it is being submitted prior to Data Lock
and unblinding of the study results." The definition of "Post-Hoc" is "After the event" - which implies they saw the data before creating the SAP, and they didn't.

— Al Musella (@AlMusella) December 23, 2022

The authors want the study repeated with no crossover. I wonder if they would allow their kids or parents to participate in such a trial, with the risk of a placebo. If they wouldn't allow their family to do it, why should we.

— Al Musella (@AlMusella) December 23, 2022

Bottom Line: This study has flaws, as do ALL phase 3 trials. They are not bad enough to disregard the conclusion that DCVAX helps patients. We need to get this approved ASAP, then we will be able to experiment with combinations that will improve these already impressive results

— Al Musella (@AlMusella) December 23, 2022

I have been to many FDA meetings both public and private. I testified at the advisory committee meetings for avastin, optune and gleolan. The trials for each of these were picked apart worse than we are seeing here for dcvax. They all were approved

— Al Musella (@AlMusella) December 24, 2022